Product evidence and status questions
Questions to ask about products discussed by Fort Worth clinics.
A product name alone is not enough for comparison. Ask the clinician to identify the formulation and proposed use, distinguish FDA approval from patient-specific compounding, explain the quality and limits of human evidence, and document risks, alternatives, pharmacy, monitoring, and total cost.
Sermorelin
Evidence and product-status questions
Evidence quality and regulatory status for Sermorelin depend on the exact product, formulation, and proposed use. Ask a licensed clinician to explain the relevant human evidence, uncertainties, risks, alternatives, approval or compounding status, and monitoring plan.
Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PMC2699646
Tesamorelin
Evidence and product-status questions
Evidence quality and regulatory status for Tesamorelin depend on the exact product, formulation, and proposed use. Ask a licensed clinician to explain the relevant human evidence, uncertainties, risks, alternatives, approval or compounding status, and monitoring plan.
Stanley TL, et al. Effects of tesamorelin on visceral fat and liver fat. JAMA. PMC8366828
GHK-Cu
Evidence and product-status questions
Evidence quality and regulatory status for GHK-Cu depend on the exact product, formulation, and proposed use. Ask a licensed clinician to explain the relevant human evidence, uncertainties, risks, alternatives, approval or compounding status, and monitoring plan.
Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide. Int J Mol Sci. 2018. PMC6073405 · Pickart L, et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int. 2015. PMC4508379
BPC-157
Evidence and product-status questions
Evidence quality and regulatory status for BPC-157 depend on the exact product, formulation, and proposed use. Ask a licensed clinician to explain the relevant human evidence, uncertainties, risks, alternatives, approval or compounding status, and monitoring plan.
Whitehouse MW, et al. BPC-157 as a cytoprotectant: review of preclinical evidence. 2025. PMC12396989
Growth hormone axis (clinical context)
Evidence and product-status questions
Evidence quality and regulatory status for Growth hormone axis (clinical context) depend on the exact product, formulation, and proposed use. Ask a licensed clinician to explain the relevant human evidence, uncertainties, risks, alternatives, approval or compounding status, and monitoring plan.
Bartke A. Growth hormone and aging: a clinical review. 2025. PMC12009952